Somatic Mutations ofIDH1andIDH2in the Myeloproliferative Neoplasms

New England Journal of Medicine

362, 369-370

DOI: 10.1056/nejmc0910063

Citation Report

#	Article	IF	Citations
1	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica, 2010, 95, 1668-1674.	1.7	177
2	Absence of R140Q mutation of isocitrate dehydrogenase 2 in gliomas and breast cancers. Oncology Letters, 2010, 1, 883-884.	0.8	7
3	IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica, 2010, 95, 1797-1798.	1.7	13
4	Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood, 2010, 116, 2122-2126.	0.6	345
5	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2010, 116, 614-616.	0.6	170
6	A single-tube, sensitive multiplex method for screening of isocitrate dehydrogenase 1 (IDH1) mutations. Blood, 2010, 116, 495-496.	0.6	12
7	Competing cell clones in myeloproliferative neoplasm. Blood, 2010, 116, 5074-5075.	0.6	2
8	IDH mutation analysis is not suitable for the routine molecular diagnostic algorithm in myeloproliferative and myelodysplastic neoplasms. Blood, 2010, 116, 5073-5074.	0.6	3
9	Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer, 2010, 10, 401.	1.1	140
10	The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting Î±-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell, 2010, 17, 225-234.	7.7	1,754
11	IDH1 and IDH2: Not Your Typical Oncogenes. Cancer Cell, 2010, 17, 215-216.	7.7	65
12	Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell, 2010, 17, 584-596.	7.7	324
13	Increased levels of 2â€hydroxyglutarate in AML patients with IDH1â€R132H and IDH2â€R140Q mutations. European Journal of Haematology, 2010, 85, 457-459.	1.1	39
14	Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations. British Journal of Haematology, 2010, 150, 83-87.	1.2	64
15	Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene, 2010, 29, 6409-6417.	2.6	259
16	WHO-defined â€˜myelodysplastic syndrome with isolated del(5q)â€™ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia, 2010, 24, 1283-1289.	3.3	88
17	IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia, 2010, 24, 1302-1309.	3.3	300
18	Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia, 2010, 24, 1096-1098.	3.3	37

#	Article	IF	Citations
19	Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia, 2010, 24, 1094-1096.	3.3	225
20	Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 2010, 24, 1128-1138.	3.3	499
21	IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia, 2010, 24, 1146-1151.	3.3	180
22	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia, 2010, 24, 1290-1298.	3.3	135
23	Metabolism and the leukemic stem cell. Journal of Experimental Medicine, 2010, 207, 677-680.	4.2	70
24	TET2 gene is not deleted in chronic myelomonocytic leukemia: a FISH retrospective study. Haematologica, 2010, 95, 1798-1800.	1.7	9
25	IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications. Haematologica, 2010, 95, 1623-1627.	1.7	23
26	Molecular basis and clonal evolution of myeloproliferative neoplasms. Haematologica, 2010, 95, 526-529.	1.7	11
27	JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology, 2010, 3, 323-337.	1.0	73
28	IDH mutations in glioma and acute myeloid leukemia. Trends in Molecular Medicine, 2010, 16, 387-397.	3.5	322
29	IDH1 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications, 2010, 398, 585-587.	1.0	58
30	IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochemical and Biophysical Research Communications, 2010, 402, 378-383.	1.0	38
31	Prognostic Impact of Isocitrate Dehydrogenase Enzyme Isoforms 1 and 2 Mutations in Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association Group. Journal of Clinical Oncology, 2010, 28, 3717-3723.	0.8	189
32	Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular Metabolism. Journal of the National Cancer Institute, 2010, 102, 932-941.	3.0	448
33	Diagnostic Testing for IDH1 and IDH2 Variants in Acute Myeloid Leukemia. Journal of Molecular Diagnostics, 2011, 13, 678-686.	1.2	46
34	Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer Journal, 2011, 1, e40-e40.	2.8	33
35	Normal and malignant megakaryopoiesis. Expert Reviews in Molecular Medicine, 2011, 13, e32.	1.6	19
36	JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment. Therapeutic Advances in Hematology, 2011, 2, 21-32.	1.1	82

#	Article	IF	Citations
37	Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium. Blood Cancer Journal, 2011, 1, e7-e7.	2.8	13
38	New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2011, 20, 961-972.	1.9	20
39	Survival of the fittest: metabolic adaptations in cancer. Current Opinion in Genetics and Development, 2011, 21, 59-66.	1.5	23
40	JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective. Blood Reviews, 2011, 25, 229-237.	2.8	43
41	Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. Leukemia and Lymphoma, 2011, 52, 1178-1187.	0.6	13
42	Development and Maintenance of Cancer Stem Cells under Chronic Inflammation. Journal of Nippon Medical School, 2011, 78, 138-145.	0.3	32
43	2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations. PLoS ONE, 2011, 6, e16812.	1.1	100
44	Targeting myeloproliferative neoplasms with JAK inhibitors. Current Opinion in Hematology, 2011, 18, 105-110.	1.2	38
45	The pathogenesis of essential thrombocythemia. Current Opinion in Hematology, 2011, 18, 323-329.	1.2	15
46	Ddx18 is essential for cell-cycle progression in zebrafish hematopoietic cells and is mutated in human AML. Blood, 2011, 118, 903-915.	0.6	43
47	EZH2 mutational status predicts poor survival in myelofibrosis. Blood, 2011, 118, 5227-5234.	0.6	242
48	Evaluation of mutations in the isocitrate dehydrogenase genes in therapyâ€related and secondary acute myeloid leukaemia identifies a patient with clonal evolution to IDH2 R172K homozygosity due to uniparental disomy. British Journal of Haematology, 2011, 152, 669-672.	1.2	10
49	Rapid identification of IDH1 and IDH2 mutations in acute myeloid leukaemia using high resolution melting curve analysis. British Journal of Haematology, 2011, 152, 493-496.	1.2	8
50	Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. British Journal of Haematology, 2011, 153, 149-167.	1.2	50
51	Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature Reviews Drug Discovery, 2011, 10, 127-140.	21.5	261
52	IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. Leukemia, 2011, 25, 178-181.	3.3	27
53	JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia, 2011, 25, 218-225.	3.3	117
54	Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. Journal of Clinical Oncology, 2011, 29, 573-582.	0.8	272

#	Article	IF	Citations
55	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	0.6	153
56	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood, 2011, 117, e198-e206.	0.6	143
57	Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies. Clinical Epigenetics, 2011, 2, 197-212.	1.8	36
58	Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate. Tumor Biology, 2011, 32, 325-333.	0.8	25
59	IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. Journal of Pathology, 2011, 224, 334-343.	2.1	834
60	Isocitrate dehydrogenase 1/2 mutational analyses and 2â€hydroxyglutarate measurements in Wilms tumors. Pediatric Blood and Cancer, 2011, 56, 379-383.	0.8	28
61	Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy, 2011, 12, 1597-1611.	0.9	25
62	Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin. Journal of Clinical Oncology, 2011, 29, 4482-4490.	0.8	420
63	The Redox Basis of Epigenetic Modifications: From Mechanisms to Functional Consequences. Antioxidants and Redox Signaling, 2011, 15, 551-589.	2.5	242
64	p53 Lesions in Leukemic Transformation. New England Journal of Medicine, 2011, 364, 488-490.	13.9	202
65	Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications. Journal of Clinical Pathology, 2011, 64, 835-844.	1.0	43
66	IDH1 and IDH2 mutations in pediatric acute leukemia. Leukemia, 2011, 25, 1570-1577.	3.3	80
67	Molecular Pathogenesis of Philadelphia Chromosome Negative Chronic Myeloproliferative Neoplasms. Current Cancer Drug Targets, 2011, 11, 20-30.	0.8	11
68	Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology, 2011, 29, 789-796.	0.8	369
69	Acute Myeloid Leukemia With IDH1 or IDH2 Mutation. American Journal of Clinical Pathology, 2011, 135, 35-45.	0.4	145
70	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Therapeutic Advances in Hematology, 2012, 3, 341-354.	1.1	50
71	Cancer-Associated Isocitrate Dehydrogenase Mutations. Oncologist, 2012, 17, 5-8.	1.9	18
72	Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro-Oncology, 2012, 14, 1465-1472.	0.6	35

#	Article	IF	Citations
73	An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro-Oncology, 2012, 14, 184-191.	0.6	145
74	BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques. Future Oncology, 2012, 8, 575-593.	1.1	4
75	IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia, 2012, 26, 475-480.	3.3	146
76	Novel splicing-factor mutations in juvenile myelomonocytic leukemia. Leukemia, 2012, 26, 1879-1881.	3.3	13
77	JAK2 inhibitors in the treatment of myeloproliferative neoplasms. Expert Opinion on Investigational Drugs, 2012, 21, 1755-1774.	1.9	16
78	The Role of Mitochondrial NADPH-Dependent Isocitrate Dehydrogenase in Cancer Cells. International Journal of Cell Biology, 2012, 2012, 1-12.	1.0	89
79	Altered expression levels of IDH2 are involved in the development of colon cancer. Experimental and Therapeutic Medicine, 2012, 4, 801-806.	0.8	30
80	Genetically-defined metabolic reprogramming in cancer. Trends in Endocrinology and Metabolism, 2012, 23, 552-559.	3.1	72
81	D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. Genes and Development, 2012, 26, 2038-2049.	2.7	257
82	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. American Journal of Hematology, 2012, 87, 1010-1016.	2.0	67
83	Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2012, 26, 993-1015.	0.9	7
84	Mitochondria and Cancer: A Growing Role in Apoptosis, Cancer Cell Metabolism and Dedifferentiation. Advances in Experimental Medicine and Biology, 2012, 942, 287-308.	0.8	119
85	Immunomodulatory agents in myelofibrosis. Expert Opinion on Investigational Drugs, 2012, 21, 1141-1154.	1.9	14
86	Role of Germline Genetic Factors in MPN Pathogenesis. Hematology/Oncology Clinics of North America, 2012, 26, 1037-1051.	0.9	17
87	IDH mutations in acute myeloid leukemia. Human Pathology, 2012, 43, 1541-1551.	1.1	103
88	Clinical importance of SF3B1 mutations in Chinese with myelodysplastic syndromes with ring sideroblasts. Leukemia Research, 2012, 36, 1428-1433.	0.4	35
89	GR SNP helps transform myelofibrosis. Blood, 2012, 120, 2934-2935.	0.6	2
90	Advances in Mitochondrial Medicine. Advances in Experimental Medicine and Biology, 2012, , .	0.8	17

#	Article	IF	Citations
91	Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms. Molecular Diagnosis and Therapy, 2012, 16, 269-283.	1.6	14
92	Activating Mutations and Targeted Therapy in Cancer. , 0, , .		3
93	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood, 2012, 119, 3203-3210.	0.6	343
94	Molecular pathogenesis of IDH mutations in gliomas. Brain Tumor Pathology, 2012, 29, 131-139.	1.1	115
95	Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells. Cell, 2012, 149, 36-47.	13.5	528
96	Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Journal of Hematology and Oncology, 2012, 5, 5.	6.9	83
97	Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood, 2012, 119, 4480-4485.	0.6	189
98	Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with highâ€dose cytarabine and idarubicin. Cancer, 2012, 118, 2665-2673.	2.0	47
99	Reactive oxygen species: Are they important for haematopoiesis?. Critical Reviews in Oncology/Hematology, 2012, 81, 257-274.	2.0	61
100	Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: Novel Pathogenetic Lesions. Seminars in Oncology, 2012, 39, 67-73.	0.8	41
101	Adverse impact of IDH1 and IDH2 mutations in primary AML: Experience of the Spanish CETLAM group. Leukemia Research, 2012, 36, 990-997.	0.4	41
102	Epigenetics and blood disorders. British Journal of Haematology, 2012, 158, 307-322.	1.2	11
103	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	2.0	107
104	Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?. Current Hematologic Malignancy Reports, 2012, 7, 78-86.	1.2	31
105	Role of TET2 Mutations in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 2012, 7, 57-64.	1.2	32
106	TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms. Annals of Hematology, 2012, 91, 533-541.	0.8	48
107	Genetic Basis of MPN: Beyond JAK2-V617F. Current Hematologic Malignancy Reports, 2013, 8, 299-306.	1.2	16
108	Epigenetic therapy of hematological malignancies: where are we now?. Therapeutic Advances in Hematology, 2013, 4, 81-91.	1.1	23

#	Article	IF	Citations
109	Genetic and epigenetic alterations of myeloproliferative disorders. International Journal of Hematology, 2013, 97, 183-197.	0.7	60
110	Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression. Advances in Immunology, 2013, 117, 1-38.	1.1	27
111	Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism. Biochemistry, 2013, 52, 4563-4577.	1.2	69
112	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
113	Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica, 2013, 98, 1058-1066.	1.7	67
114	Screening forIDHmutations in chronic myelomonocytic leukemia. Leukemia and Lymphoma, 2013, 54, 406-407.	0.6	4
115	Polycythemia vera and essential thrombocythemia. Current Opinion in Hematology, 2013, 20, 169-175.	1.2	12
116	The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms. Frontiers in Oncology, 2013, 3, 169.	1.3	44
117	Molecular basis and clonal evolution of myeloproliferative neoplasms. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1889-1896.	1.4	8
118	Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1028-1035.	0.6	30
119	The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 2013, 19, 327-335.	3.2	40
120	Inherited predisposition to myeloproliferative neoplasms. Therapeutic Advances in Hematology, 2013, 4, 237-253.	1.1	49
121	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 2013, 122, 2877-2887.	0.6	186
122	Molecular Distinction of Chondrosarcoma From Chondroblastic Osteosarcoma Through IDH1/2 Mutations. American Journal of Surgical Pathology, 2013, 37, 787-795.	2.1	92
123	The Distribution and Significance of IDH Mutations in Gliomas. , 0, , .		5
124	A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop. Oncogene, 2014, 33, 4114-4122.	2.6	12
125	The evolving genomic landscape of myeloproliferative neoplasms. Hematology American Society of Hematology Education Program, 2014, 2014, 287-296.	0.9	62
126	Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5401-10.	3.3	238

#	Article	IF	Citations
127	Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Current Opinion in Hematology, 2014, 21, 65-71.	1.2	33
128	Isocitrate Dehydrogenase-1 Is Mutated in Inflammatory Bowel Diseaseâ€“associated Intestinal Adenocarcinoma With Low-grade Tubuloglandular Histology but Not in Sporadic Intestinal Adenocarcinoma. American Journal of Surgical Pathology, 2014, 38, 1147-1156.	2.1	32
129	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes and Development, 2014, 28, 479-490.	2.7	70
130	From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood, 2014, 123, 3714-3719.	0.6	174
131	Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. Leukemia Research, 2014, 38, 649-659.	0.4	38
132	A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. Best Practice and Research in Clinical Haematology, 2014, 27, 83-93.	0.7	12
133	Driver mutations of cancer epigenomes. Protein and Cell, 2014, 5, 265-296.	4.8	139
135	DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia, 2014, 28, 1774-1783.	3.3	225
136	Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes. PLoS ONE, 2015, 10, e0131998.	1.1	55
137	Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLoS ONE, 2015, 10, e0133813.	1.1	88
138	Targeting Mitochondria: A Powerhouse Approach to Cancer Treatment. , 2015, , 263-276.		1
139	Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer Journal, 2015, 5, e366-e366.	2.8	190
140	Multi-Targeted Approach to Treatment of Cancer. , 2015, , .		1
141	Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders. Blood Cells, Molecules, and Diseases, 2015, 54, 286-291.	0.6	18
142	Enigmas of IDH mutations in hematology/oncology. Experimental Hematology, 2015, 43, 685-697.	0.2	22
143	Protein kinase CÉ› inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients. Leukemia, 2015, 29, 2192-2201.	3.3	19
144	Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 550-555.	0.2	30
145	Secondary Acute Myeloid Leukemias Arising From Philadelphia Chromosome Negative Myeloproliferative Neoplasms: Pathogenesis, Risk Factors, and Therapeutic Strategies. Current Hematologic Malignancy Reports, 2015, 10, 112-117.	1.2	16

#	Article	IF	Citations
146	Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. American Journal of Surgical Pathology, 2015, 39, 454-461.	2.1	25
147	A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma. Biochemical and Biophysical Research Communications, 2015, 459, 636-642.	1.0	4
148	A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas. Biochemical and Biophysical Research Communications, 2015, 466, 733-739.	1.0	13
149	Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations. Current Hematologic Malignancy Reports, 2015, 10, 335-343.	1.2	20
150	Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas. Brain Tumor Pathology, 2015, 32, 3-11.	1.1	62
151	IDH1/2 mutation detection in gliomas. Brain Tumor Pathology, 2015, 32, 79-89.	1.1	44
152	Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer, 2015, 121, 502-516.	2.0	120
154	In-VivoProton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists. Korean Journal of Radiology, 2016, 17, 620.	1.5	31
155	The evolution and clinical relevance of prognostic classification systems in myelofibrosis. Cancer, 2016, 122, 681-692.	2.0	17
156	Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radical Biology and Medicine, 2016, 100, 175-181.	1.3	137
157	Pathogenesis of Myeloproliferative Disorders. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 101-126.	9.6	38
158	Somatic mutations of isocitrate dehydrogenases 1 and 2 are prognostic and follow-up markers in patients with acute myeloid leukaemia with normal karyotype. Radiology and Oncology, 2016, 50, 385-393.	0.6	16
160	Prognosis of Primary Myelofibrosis in the Genomic Era. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S105-S113.	0.2	12
161	Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability. Human Molecular Genetics, 2016, 25, 3524-3538.	1.4	8
162	IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia, 2016, 30, 980-984.	3.3	88
163	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia, 2017, 31, 2020-2028.	3.3	97
164	Management of myelofibrosis: JAK inhibition and beyond. Expert Review of Hematology, 2017, 10, 459-477.	1.0	11
165	Looking to the metabolic landscapes for prostate health monitoring. Prostate International, 2017, 5, 85-88.	1.2	7

#	Article	IF	Citations
166	Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome. Genes Chromosomes and Cancer, 2017, 56, 354-362.	1.5	12
167	Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms. Haematologica, 2017, 102, 7-17.	1.7	74
168	From leeches to personalized medicine: evolving concepts in the management of polycythemia vera. Haematologica, 2017, 102, 18-29.	1.7	16
169	Mutations in myeloproliferative neoplasms â€“ their significance and clinical use. Expert Review of Hematology, 2017, 10, 961-973.	1.0	19
170	Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms. Leukemia Research, 2017, 63, 78-84.	0.4	10
171	Leukemic Transformation in Myeloproliferative Neoplasms. Mayo Clinic Proceedings, 2017, 92, 1118-1128.	1.4	83
172	Chemotherapy for post-myelofibrosis acute myeloid leukemia: eradication of the leukemic clone but not the MPN clone. Leukemia and Lymphoma, 2017, 58, 749-751.	0.6	4
173	Exploring the key genes and pathways in enchondromas using a gene expression microarray. Oncotarget, 2017, 8, 43967-43977.	0.8	7
174	Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. Critical Reviews in Oncology/Hematology, 2018, 126, 64-79.	2.0	12
175	Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status. Leukemia, 2018, 32, 450-461.	3.3	54
176	Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Annals of Hematology, 2018, 97, 443-451.	0.8	36
177	Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. American Journal of Surgical Pathology, 2018, 42, 569-577.	2.1	9
178	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
179	How I treat the blast phase of Philadelphia chromosomeâ€“negative myeloproliferative neoplasms. Blood, 2018, 132, 2339-2350.	0.6	27
180	Enasidenib. Recent Results in Cancer Research, 2018, 212, 187-197.	1.8	4
181	Small Molecules in Hematology. Recent Results in Cancer Research, 2018, , .	1.8	6
182	Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: A Case Series and Review of the Literature. Frontiers in Oncology, 2018, 8, 32.	1.3	7
183	Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies. Cancers, 2018, 10, 49.	1.7	31

#	Article	IF	Citations
184	Quantitative Profiling of Oncometabolites in Frozen and Formalin-Fixed Paraffin-Embedded Tissue Specimens by Liquid Chromatography Coupled with Tandem Mass Spectrometry. Scientific Reports, 2019, 9, 11238.	1.6	8
185	Application of natural products derivatization method in the design of targeted anticancer agents from 2000 to 2018. Bioorganic and Medicinal Chemistry, 2019, 27, 115150.	1.4	14
186	IDH1 as a Cooperating Mutation in AML Arising in the Context of Shwachman-Diamond Syndrome. Frontiers in Oncology, 2019, 9, 772.	1.3	8
187	JAK2-mutated acute myeloid leukemia: comparison of next-generation sequencing (NGS) and single nucleotide polymorphism array (SNPa) findings between two cases. Autopsy and Case Reports, 2019, 9, e2018084.	0.2	4
188	Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options. International Journal of Molecular Sciences, 2019, 20, 1839.	1.8	46
189	Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Cancer Discovery, 2019, 9, 756-777.	7.7	18
190	Mutational profiling in myelofibrosis: implications for management. International Journal of Hematology, 2020, 111, 192-199.	0.7	9
191	Acute myeloid leukemia with isolated del(5q) is associated with IDH1/IDH2 mutations and better prognosis when compared to acute myeloid leukemia with complex karyotype including del(5q). Modern Pathology, 2020, 33, 566-575.	2.9	1
192	Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 126825.	1.0	13
193	Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity. Modern Pathology, 2020, 33, 1056-1064.	2.9	35
194	Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms. Cancers, 2020, 12, 2891.	1.7	13
195	SUMOylation enhances the activity of IDH2 under oxidative stress. Biochemical and Biophysical Research Communications, 2020, 532, 591-597.	1.0	7
196	Genetic factors rather than blast reduction determine outcomes of allogeneic HCT in BCR-ABLâ€“negative MPN in blast phase. Blood Advances, 2020, 4, 5562-5573.	2.5	28
197	Epigenetic Therapies for Cancer. New England Journal of Medicine, 2020, 383, 650-663.	13.9	289
198	Splicing Anomalies in Myeloproliferative Neoplasms: Paving the Way for New Therapeutic Venues. Cancers, 2020, 12, 2216.	1.7	17
199	Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias. Cancers, 2020, 12, 2427.	1.7	13
200	Teleological Role of L-2-Hydroxyglutarate Dehydrogenase in the Kidney. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	8
201	Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms. Expert Review of Hematology, 2020, 13, 1349-1359.	1.0	2

#	Article	IF	Citations
202	Leukemia secondary to myeloproliferative neoplasms. Blood, 2020, 136, 61-70.	0.6	80
203	Genomic heterogeneity in myeloproliferative neoplasms and applications to clinical practice. Blood Reviews, 2020, 42, 100708.	2.8	10
204	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. Genes, 2020, 11, 749.	1.0	30
205	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	3.3	37
206	Late appearance of eosinophilia in myeloid blast phase of myeloid neoplasm with rearrangement of PDGFRÎ². Leukemia and Lymphoma, 2020, 61, 1736-1739.	0.6	0
207	Mouse Models of Myeloid Malignancies. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a035535.	2.9	3
208	IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis. Blood, 2021, 137, 945-958.	0.6	16
209	TNFAIP8 drives metabolic reprogramming to promote prostate cancer cell proliferation. International Journal of Biochemistry and Cell Biology, 2021, 130, 105885.	1.2	5
210	Synthesis and Evaluation of 3-(Indol-3-yl)-4-(pyrazolo[3,4- c]pyridazin-3-yl)maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors. Chinese Journal of Organic Chemistry, 2021, , 1991.	0.6	0
211	Accelerated Phase of Myeloproliferative Neoplasms. Acta Haematologica, 2021, 144, 484-499.	0.7	26
213	Myeloid, mast cell, histiocytic and dendritic cell neoplasms and proliferations involving the spleen. Seminars in Diagnostic Pathology, 2021, 38, 144-153.	1.0	0
214	What are the molecular mechanisms driving the switch from MPNs to leukemia?. Best Practice and Research in Clinical Haematology, 2021, 34, 101254.	0.7	3
215	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Advances, 2021, 5, 2156-2164.	2.5	33
216	Epigenetic Dysregulation of Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 237-251.	0.9	4
217	Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera. International Journal of Molecular Sciences, 2021, 22, 5042.	1.8	14
218	Metabolomics bridging proteomics along metabolites/oncometabolites and protein modifications: Paving the way toward integrative multiomics. Journal of Pharmaceutical and Biomedical Analysis, 2021, 199, 114031.	1.4	8
219	Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 41-54.	1.2	8
220	Additional mutations in IDH1/2â€mutated patients with acute myeloid leukemia. International Journal of Laboratory Hematology, 2021, 43, 1483-1490.	0.7	5

#	Article	IF	Citations
221	Mutant Idh2 Cooperates with a NUP98-HOXD13 Fusion to Induce Early Immature Thymocyte Precursor ALL. Cancer Research, 2021, 81, 5033-5046.	0.4	7
222	Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cells. Molecular Cell, 2021, 81, 3833-3847.e11.	4.5	10
223	Acute Myeloid Leukemia Evolving from Myeloproliferative Neoplasms: Many Sides of a Challenging Disease. Journal of Clinical Medicine, 2021, 10, 436.	1.0	12
224	Secondary AML. Hematologic Malignancies, 2021, , 71-101.	0.2	0
225	Neoplastische BildungsstÃ¶rungen der HÃmatopoiese mit erhaltener Ausreifung. , 2019, , 47-87.		2
226	JAK2/IDH-mutantâ€“driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. Journal of Clinical Investigation, 2018, 128, 789-804.	3.9	66
227	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. PLoS ONE, 2012, 7, e43090.	1.1	97
228	The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis. Journal of Clinical Medicine Research, 2016, 8, 29-39.	0.6	13
229	Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget, 2011, 2, 485-490.	0.8	44
230	Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs). Stem Cell Investigation, 2015, 2, 16.	1.3	12
231	The Current Molecular Site of the Myeloproliferative Neoplasms - TET-ÃtÃªte with the JAKpot but no LNK so far to Resolve Complexity. Journal of Leukemia (Los Angeles, Calif), 2013, 01, .	0.1	1
232	Molecular biology of Philadelphia-negative myeloproliferative neoplasms. Revista Brasileira De Hematologia E Hemoterapia, 2012, 34, 150-155.	0.7	14
233	Synthesis and Evaluation of 3-(Indol-3-yl)-4-(Pyrazolo[3,4-c]Pyridazin-3-yl)-Maleimides as Potent Mutant Isocitrate Dehydrogenase-1 Inhibitors. Pharmaceutical Chemistry Journal, 2021, 55, 655-664.	0.3	0
234	IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F. Blood, 2011, 118, 1751-1751.	0.6	5
235	A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy. , 2012, , 203-214.		0
236	Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms. , 2012, , 131-145.		0
237	Update on the Biology of Myeloproliferative Neoplasms. , 2012, , 3-10.		0
238	Chronic Myeloproliferative Disorders:From Molecular Pathogenesis to Targeted Therapy. , 2012, , 241-276.		0

#	Article	IF	Citations
241	Molecular genetics of myelofibrosis and its associated disease phenotypes. Translational Medicine @ UniSa, 2014, 8, 53-64.	0.8	7
242	The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1825-1831.	0.5	1
243	Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies. Cancers, 2021, 13, 5605.	1.7	3
244	Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease. Metabolites, 2022, 12, 46.	1.3	4
245	Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms. International Journal of Molecular Sciences, 2022, 23, 1013.	1.8	8
246	Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. International Review of Cell and Molecular Biology, 2022, 366, 83-124.	1.6	12
247	Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasmâ€“blast phase. JCI Insight, 2022, 7, .	2.3	3
248	BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms. Epigenomics, 2022, 14, 391-403.	1.0	1
252	Targeting Metabolic Reprogramming of T-Cells for Enhanced Anti-Tumor Response. Biologics: Targets and Therapy, 2022, Volume 16, 35-45.	3.0	3
253	Diagnostic and Therapeutic Perspectives Associated to Cobalamin-Dependent Metabolism and Transcobalaminsâ€™ Synthesis in Solid Cancers. Nutrients, 2022, 14, 2058.	1.7	5
254	Accelerated and blast phase myeloproliferative neoplasms. Best Practice and Research in Clinical Haematology, 2022, 35, 101379.	0.7	5
255	Characterization of pyruvate metabolism and citric acid cycle patterns predicts response to immunotherapeutic and ferroptosis in gastric cancer. Cancer Cell International, 2022, 22, .	1.8	8
256	Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood, 2023, 141, 1909-1921.	0.6	31
257	Less Common Triple-Negative Breast Cancers. , 2022, , 463-573.		0
258	Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology. Diagnostics, 2023, 13, 163.	1.3	1
259	ENABLE: treatment combination including decitabine and venetoclax in acute myeloid leukemia secondary to myeloproliferative neoplasms. Future Oncology, 0, , .	1.1	0
260	Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution. Human Pathology, 2023, 136, 63-74.	1.1	2
263	Molecular Landscape and Personalized Prognostic Prediction of MPNs. , 2023, , 501-513.		0

#	Article	IF	Citations